The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
4 reports and counting
Abcuro Raises $66M Series D for Inclusion Body Myositis Trial
Abcuro raised a $66 million Series D led by New Leaf Venture Partners to fund a new potentially registrational study of ulviprubart in inclusion body myositis.
Abcuro Raises $200M in Series C
Abcuro, a HealthTech company based in Cambridge, MA, has raised $200M in Series C at a $1.5B valuation led by RA Capital, Arch Venture Partners.
Abcuro raises $200M Series C at $1.5B valuation
Abcuro raises $200M in Series C at $1.5B valuation. Antibody therapeutics for autoimmune diseases...
Abcuro Raises $200M Series C to Transform Biotech
Abcuro has secured $200M Series C in funding to accelerate growth and innovation in the biotech sector. Precision oncology company discovering and developing novel cancer immunotherapies targeting tumor microenvironments...
Showing 4 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.